H.C. Wainwright Maintains Their Buy Rating on Bellerophon (BLPH)

By Jason Carr

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Bellerophon (NASDAQ: BLPH), with a price target of $5. The company’s shares closed yesterday at $2.53.

Fein wrote:

“Valuation and risks. Our price target of $5/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc.”

According to TipRanks.com, Fein is a 4-star analyst with an average return of 4.3% and a 45.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bellerophon with a $5 average price target.

See today’s analyst top recommended stocks >>

Based on Bellerophon’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.47 million. In comparison, last year the company had a GAAP net loss of $3.93 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bellerophon Therapeutics, Inc clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.